SAN FRANCISCO, Calif. — Weave Bio, a pioneer in AI-native regulatory automation management solutions, announced it has raised $20 million in Series A financing, bringing its total funding to $36 million. The round was led by USVP with participation from Innovation Endeavors, Magnetic Ventures, Character, TMV, and Serrado Capital.
The Weave Platform is designed to transform how pharmaceutical companies, biotech firms, contract research organizations, and regulatory consultants manage the complex documentation and submission processes that underpin drug development. Built as an AI-native solution, the platform automates data organization, authoring, review, and publishing across the entire regulatory lifecycle of a therapeutic, from early development through market application and post-market updates.
“Regulatory workflows are the backbone of a therapeutic candidate’s success, requiring scientific precision, strategic expertise, and meticulous execution,” said Brandon Rice, CEO and co-founder of Weave Bio. “With the Weave Platform, a new paradigm is emerging wherein every stage of the workflow is intelligently infused with AI, dramatically accelerating the process and empowering teams to focus on those areas that uniquely benefit from human judgment and expertise. This new funding will enable us to expand the reach of our platform and extend its capabilities to provide our customers with even greater speed and control.”
Weave Bio plans to use the proceeds to accelerate product development, expand its commercial operations, and extend its platform’s coverage across the full regulatory lifecycle. The company also intends to broaden its reach into international markets, including Europe, Japan, and Latin America, and to build advanced AI features that can deliver deeper insights into therapeutic portfolios, enabling more strategic decision-making throughout drug development.
“Weave is redefining regulatory workflows with the first AI-native platform built for drug development. It’s modern, intuitive, and built to scale—exactly the type of innovation we look to back at USVP,” said Matt Garratt, General Partner at USVP. “We’re excited to support the team as they help bring life-changing therapies to patients faster.”
Weave Bio’s platform represents a growing shift toward automation and intelligence in life sciences operations, aiming to reduce the time, cost, and complexity associated with regulatory processes while improving quality and compliance across the industry.
